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Michael Gross looks at the problems that beset plans for the country’s 
pioneering genome project.
Iceland plans reigned inBack in 2000, when the imminent 
completion of the human genome 
fired the imagination of many 
biotech entrepreneurs and the 
internet bubble had yet to burst, 
many people were considering 
the logical next step after the 
genome. After establishing the 
three billion letters of DNA code 
that we all have in common, the 
hunt was on for the much smaller 
number of letters that are variable 
between individuals and that are 
held responsible for a range of 
problems, from inherited disease 
through to different responses to 
prescription drugs.
Projects that sought to link 
medical, genealogical and genetic 
information in an attempt to 
crack the code of human genetic 
variability were seen shooting 
up everywhere, using small gene 
pools like isolated Italian villages or larger ones, like the entire 
nations of Iceland and Estonia 
(Curr. Biol. (2001), 11, R1).
One of the earliest 
starters in the new field of 
pharmacogenomics was the 
Icelandic genome project, 
masterminded by geneticist Kari 
Stefansson and spearheaded 
by his company Decode 
Genetics. Stefansson managed 
to enthuse politicians and large 
parts of the general public in 
Iceland with his promises of 
turning the peculiarities of their 
nation — few founders, long 
isolation, good genealogical 
record-keeping — into biotech 
gold. By buying shares in the 
company, all Icelanders would 
be able to make a profit from the 
research into their own genetic 
heritage. As early as 1998, after 
intensive public debate, the Icelandic parliament approved a 
bill enabling the establishment of 
a central medical database, where 
medical information was to be 
linked with genealogical details 
and gene sequences obtained 
from blood samples. 
As a result of the public debate, 
a watchdog was created to 
control the power of Decode 
over the participants. While the 
default option was that all medical 
records would be included in 
the database, everybody who 
wished to do so could opt out 
of the project. Given these 
precautions and the highly 
democratic process that led to 
this arrangement, what could 
possibly go wrong? 
By 2002, however, the Icelandic 
genome bubble had burst on the 
stock market. Maybe politicians 
and biotech entrepreneurs 
made more promises than they 
could keep in the short term, or 
maybe the hype generated by an Side step: Plans for a national genomics database for Icelanders have faltered. (Photo: Johannes Long/Photolibrary.)
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A UK project to study genetics 
alongside health and lifestyle 
data, piloted in Manchester, has 
proved a success in no small part 
to the specific consent sought 
from participants by researchers. 
This pilot has now turned into 
the largest study of the genetic 
and environmental causes of 
disease rolled out across the UK. 
The UK Biobank aims to obtain 
DNA samples from up to 500,000 
people aged 40–69 and track their 
health. It is hoped the database 
will be used to find cures for killer 
illnesses such as heart disease, 
diabetes and cancer. The project 
received unanimous support from 
a team of international experts 
and its backers this summer 
following the Manchester pilot.
Letters will be sent to men 
and women in the target group 
by the end of the year, inviting 
them to attend one of a network 
of assessment centres to be 
set up in locations around the 
UK. Over the next three to four 
years, there will be around 35 
centres in the UK, each open for 
about six months. The centres 
will be located in areas where 
there are about 150,000 men and 
women aged 40–69 living within a 
15  kilometre radius.
The project will gather, store 
and protect a vast bank of 
medical data and material. 
The aim is to give accredited 
researchers a rich resource which 
they can use to examine how 
the complex interplay of genes, 
lifestyle and environment affects 
our risk of disease.
The £61 million project is being 
funded by the Medical Research 
Britain has won both academic 
and public support for a major 
human genomics and health 
project. Nigel Williams reports.
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Agreed: Support from people in Manchester in the pilot study has boosted the plan 
to go national for a long-term genomics database. (Photo: Marketing Manchester/
David Oates.)excess of public enthusiasm for 
the project just became a fatal 
stampede. The fact of the matter 
is that the shares in Decode that 
were traded on the unregulated 
Icelandic market at that time went 
to unrealistic heights of over $60, 
and then collapsed dramatically 
to the area of well below $6. 
Even though Decode has 
reported some scientific progress 
since that time, including the 
discovery of gene variants 
responsible for some cases of 
prostate cancer, schizophrenia, 
and cardiovascular disease, the 
company’s financial fortunes 
never fully recovered from this 
crash. At the time of writing, 
NasDaq listed Decode shares 
trade at $4.97, nearly 50 per cent 
down from the price one year 
earlier. 
With the economic downturn 
and the newspaper reports about 
small investors ruined by it came 
a growing concern about the 
privacy issues. More and more 
Icelanders made use of their 
right to opt out of the medical 
database. Court cases were 
fought, and press reports have 
now pronounced the national 
medical database as dead. 
Decode’s press department has 
pumped out more than 40 press 
releases so far this year, not one 
of which has a topic related to the 
medical database that everybody 
talked about earlier.
Instead, Decode has turned 
into a more traditional biotech 
company and focused on drug 
discovery based on a few links 
between gene variants and 
common diseases that it has 
discovered so far. Products in 
its development pipeline include 
a drug for patients with specific 
genetic risk factors for heart 
attacks (phase III) and one for 
the treatment of peripheral artery 
disease (phase II). The change 
of direction is underlined by 
a few top-level appointments 
the company made this year, 
including that of Peter Goodfellow 
(formerly GlaxoSmithKline) to its 
board of directors. Genomics is 
likely to take a new turn here now.
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